DCP/PREVENT-funded Project Presentations at the 2024 AACR Annual Meeting

Consider attending these DCP PREVENT-funded project presentations at AACR to learn about preclinical development of innovative interventions and biomarkers for cancer prevention and interception.

DCP CADRG Poster Sessions – AACR 2024

Apr. 7, 2024, 1:30 p.m. - 5:00 p.m.

762 - The combination of EPA and naproxen suppresses colon tumorigenesis via altering the TME, and promoting epithelial maturation in cancerous crypts
R. Beach¹, M. Martinez¹, V. Gunasekharan², D. W. Rosenberg¹;
1UConn Health, Farmington, CT, ²NIH/NCI, Bethesda, MD
PREVENT Contract 75N91019D00019, Task Order 75N91019F00132

Apr. 8, 2024, 9:00 a.m. - 12:30 p.m.

1445 - Emergence of frameshift mutations during tumorigenesis in VCMsh2 mouse model of Lynch syndrome
Y. Song¹, L. Wei², S. S. Baxter¹, B. Somerville¹, H. Loomans-Kropp³, C. Sanders¹, R. N. Baugher¹, S. D. Mellott¹, T. B. Young¹, H. E. Lawhorn¹, T. M. Plona¹, Q. Hu², S. Liu², A. Hutson², S. Difilippantonio¹, L. Pinto¹, S. M. Lipkin⁴, M. Kloor⁵, S. Sei³, R. H. Shoemaker³;
¹Frederick National Laboratory for Cancer Research, Frederick, MD, ²Roswell Park Comprehensive Cancer Center, Buffalo, NY, ³National Cancer Institute, Bethesda, MD, ⁴Weill Cornell Medical College, New York, NY, ⁵University of Heidelberg, Heidelberg, Germany
PREVENT Contract HHSN261201500039I, Task Order HHSN26100003

Apr. 9, 2024, 9:00 a.m. - 12:30 p.m.

4778 - Development of self-amplifying RNA vaccines targeting prostate tissue-restricted and tumor-associated antigens
R. H. Shoemaker¹, J. H. Erasmus², P. Berglund², J. D. Marshall³, Y. Koboziev³, B. M. Beckman³, B. D. Cholewa¹, S. G. Reed²;
¹National Cancer Institute, Bethesda, MD, ²HDT Bio, Seattle, WA, ³Frederick National Laboratory for Cancer Research, Frederick, MD
PREVENT Contract 75N91019D00012, Task Order 75N91020F00001 (Efficacy); saRNA vaccine development on Leidos Contract at FNL

Apr. 9, 2024, 1:30 p.m. - 5:00 p.m.

5276 - Immunomodulatory activity of intermittent low-dose erlotinib plus sulindac: Implications for hereditary and sporadic colorectal cancer
C. Tripathi¹, J. E. Tovar Perez¹, S. Kapoor¹, A. Muhsin¹, W. Dashwood¹, Y. Demirhan¹, M. Demirhan¹, A. Shapiro¹, A. Mohammed², S. Sei², P. H. Brown³, M. I. Savage³, E. Vilar³, P. Rajendran¹, R. H. Dashwood¹;
¹Texas A&M University, Houston, TX, ²National Cancer Institute, Rockville, MD, ³The University of Texas MD Anderson Cancer Center, Houston, TX
PREVENT Contract 75N91019D00021, Task Order 75N91019F00130

Apr. 10, 2024, 9:00 a.m. - 12:30 p.m.

7297 - Inhibition of lung tumorigenesis and potentiation of cancer preventive vaccines by a small molecule CA170 targeting the immune checkpoint protein VISTA
Q. Zhang¹, J. Pan¹, D. Xiong¹, Y. Wang¹, M. S. Miller², M. You¹;
¹Houston Methodist Research Institute, Houston, TX, ²National Cancer Institute, Bethesda, MD
PREVENT Contract 75N91019D00020, Task Order 75N91021F00001

Apr. 10, 2024, 9:00 a.m. - 12:30 p.m.

7299 - Preventing CRC progression in FAP rat model using a combinational targeting of TRAIL signaling and inflammation
V. Madka1, G. Pathuri¹, K. Venkatachalam¹, S. P. Singh¹, A. Singh¹, N. Stratton¹, S. Lightfoot¹, S. Sei², M. S. Miller², C. V. Rao¹;
¹OU Health Stephenson Cancer Center, Oklahoma City, OK, ²National Cancer Institute, Rockville, MD
PREVENT Contract 75N91019D00020, Task Order 75N91020F00004

Apr. 10, 2024, 9:00 a.m. - 12:30 p.m.

7302 - Effect of estrogen receptor modulator bazedoxifene on progression of carcinogen induced bladder cancer in female F344 rats
V. Madka¹, G. Pathuri¹, S. P. Singh¹, S. Chiliveru¹, A. Singh¹, A. Bao¹, N. Stratton¹, C. J. Grubbs², S. Sei³, J. Clifford³, B. Cholewa³, C. V. Rao¹;
1OU Health Stephenson Cancer Center, Oklahoma City, OK, 2University of Alabama at Birmingham, Birmingham, AL, 3National Cancer Institute, Rockville, MD
PREVENT Contract 75N91019D00020, Task Order 75N91020F00005

NCI-NIH Sponsored Session (non-poster)

Apr. 8, 2024, 10:15 a.m. - 10:16 a.m.

Moderator
Robert H. Shoemaker, Ph.D., National Cancer Institute, NIH

NIH04: - NCI Funding Opportunities in Cancer Prevention and Interception